PPARA and fatty liver disease: In MAFLD, PPARα suppresses hepatic steatosis by upregulating genes involved in β-oxidation (CPT1A, carnitine palmitoyltransferase 1A; ACOX1, acyl-CoA oxidase 1) and inhibiting de novo lipogenesis (DNL) (Table 1) [15].